Date: 2015-03-06
Type of information: Collaboration agreement
Compound: monoclonal antibodies
Company: Cellectis (France) ModiQuest Research (The Netherlands)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 6, 2015, ModiQuest Research BV, a Dutch antibody services company, announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s). During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™. Founded in 2005 and located in Oss (The Netherlands), ModiQuest Research specializes in the generation of monoclonal antibodies against difficult target antigens. Using its proprietary ModiFuse™ (electrofusion hybridoma), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest Research generates monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human against virtually any target.
Financial terms: Financial details of the collaboration were not disclosed.
Latest news:
